glp-1 amylin Inside the Boom: What a Biotech Analyst and PhD/Nutritionist Thinks Glucagon-Like Peptide-1 Based Therapies: A

In the landmark SURPASS-2 clinical trial, Mounjaro achieved A1C reductions of up to 2.3% versus 1.9% for injectable semaglutide, while producing approximately 2.5 times greater weight loss (12.4 kg vs 6.2 kg)

GLP-1 therapy partially overrides this response

In large-scale longer-term cardiovascular outcomes trials [47, 48, 84], long-term DPP-4 inhibition was associated with no change or a small decline in glomerular function that persisted during the entire duration of follow-up (up to 4 years)

The equivalent injectable dose would therefore be approximately 2mg to 2.4mg weekly, since injectable bioavailability approaches 100%